This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.
Voluntarily sign the Informed Consent Form.
Age ≥ 12 years old and <18 years old, weight ≥ 40 kg.
With a diagnosis of SAR, with or without allergic conjunctivitis, and the SAR duration was ≥ 2 years.
Not enough washing-out period for previous therapies.
With other poorly controlled serious diseases or chronic conditions.
With any conditions that are not suitable for participation in this study by investigators.